CLAIMS:

1. An isolated polynucleotide comprising the nucleic acid sequence of SEQ ID NO: 1 or a variant thereof or nucleic acid sequences complementary thereto and variants thereof.

2. The isolated polynucleotide of claim 1, wherein the variant comprises a nucleic acid sequence selected from SEQ ID NO: 2, 3, 6, 7, 8 and 9 or a variant thereof.

3. A nucleic acid construct comprising the isolated polynucleotide of claim 1 or 2.

4. A host cell comprising the nucleic acid construct of claim 3.

5. An isolated polypeptide comprising the amino acid sequence of SEQ ID NO: 4, 5, 14, 15 or a variant thereof.

6. A pharmaceutical composition comprising the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 or the isolated polypeptide of claim 5 and a pharmaceutically acceptable carrier.

7. An adjuvant formulation comprising the isolated polynucleotide of claim 1 or 2 or the isolated polypeptide of claim 5.

8. A vaccine or therapeutic composition comprising the isolated polynucleotide of claim 1 or 2 or the isolated polypeptide of claim 5 and a vaccine antigen.

9. The isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, for use as a medicament.

10. The isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, for use in the treatment of a disorder characterised by altered levels of one or more of CCR1, CCR4, CCR5, CCR6 and CCR8 or their binding chemokines.

11. The isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, for use in the treatment of a disorder, wherein the disorder is selected from cancer, HSV infection, HIV infection or HIV/AIDS, Alzheimer's and diseases having an autoimmune inflammatory component.

12. The isolated polynucleotide, nucleic acid construct, isolated polypeptide, the pharmaceutical composition, or the vaccine or therapeutic composition for use according to claim 11, wherein the disorder is HSV infection, and wherein preferably the HSV infection is acute, reactivated, persistent and/or latent.

13. The isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, for use in reducing reactivation of an infection or recurrence of a disease.

14. The isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, for use in reducing transmission of an infection.

15. A method for the treatment of a disorder characterised by altered levels of one or more of CCR1, CCR4, CCR5, CCR6 and CCR8, or their binding chemokines, the method comprising administering the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, to a patient in need thereof.

16. The method of claim 15, wherein the disorder is selected from one of cancer, HIV infection or HIV/AIDS, HSV infection, Alzheimer's and diseases having an autoimmune inflammatory component.

17. The method of claim 16, wherein the disorder is HSV infection, and wherein preferably the HSV infection is acute, reactivated, persistent and/or latent.

18. A method of reducing at least one of:

a) acute infection or disease

b) latency of an infection

c) establishment of a latent infection

d) reactivation of an infection or recurrence of disease, and

e) transmission of an infection,

the method comprising administering the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, to a patient in need thereof.

19. Use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8 in the manufacture of a medicament.

20. Use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8 in the manufacture of a medicament for the treatment of a disorder characterised by altered levels of one or more of CCR1, CCR4, CCR5, CCR6 and CCR8 or their binding chemokines.

21. Use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8 in the manufacture of a medicament for the treatment of a disorder, wherein the disorder is selected from cancer, HSV infection, HIV infection or HIV/AIDS, Alzheimer's and diseases having an autoimmune inflammatory component.

22. The use of claim 21, wherein the disorder is HSV infection, and wherein preferably the HSV infection is acute, reactivated, persistent and/or latent.

23. Use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8 in the manufacture of a medicament for reducing recurrence of disease or reactivation of an infection.

24. Use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8 in the manufacture of a medicament for reducing transmission of an infection.

25. A method of altering the activation of at least one cytokine receptor, the method comprising administering the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3 or the isolated polypeptide of claim 5 to a target cell or to a patient.

26. The method of claim 25, wherein the cytokine receptor is selected from CCR1, CCR4, CCR5, CCR6 and CCR8.

27. The use of the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, or the isolated polypeptide of claim 5 as an immunogenic adjuvant or an immune therapeutic.

28. A method of identifying a patient that carries integrated iciHHV-6A, expresses the iciU83A gene or iciU83A-N transcript, the method comprising obtaining a nucleic acid sample from a patient and carrying out amplification using the primer pair defined in SEQ ID Nos 10 and 11.

29. A kit for treating a disorder characterised by altered levels of one or more of CCR1, CCR4, CCR5, CCR6 and CCR8, or their binding chemokines, the kit comprising the isolated polynucleotide of claim 1 or 2, the nucleic acid construct of claim 3, the isolated polypeptide of claim 5, the pharmaceutical composition of claim 6, or the vaccine or therapeutic composition of claim 8, together with instructions for treating said disorder.

30. A kit for identifying a patient that carries integrated iciHHV-6A, expresses the iciU83A gene or iciU83A-N transcript, the kit comprising primers for amplification of the integrated sequence, the primers comprising a sequence as defined in SEQ ID NO: 10 or 11.